Obesity Drug Access Grows as Novo, Lilly Sell Direct to Employers, Bypass PBMs

 

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach that would bypass traditional drug sales channels in an effort to expand access to the costly weight-loss medicines.

The drugmakers will offer Zepbound and Wegovy to companies starting Jan. 1 through Waltz Health, a firm that helps employers purchase cheaper medications. The shots will be available to employers at upfront, fixed prices, avoiding the rebates and fees that accompany traditional sales through middlemen who manage pharmacy benefits for many companies.

https://www.bloomberg.com/news/articles/2025-11-21/obesity-drug-access-grows-as-novo-lilly-sell-direct-to-employers